Deprescribing in Patients With Cardiovascular Disease Experiencing Polypharmacy: A Scientific Statement From the American Heart Association
Listen to this summary
The authors aim to address the challenges of managing polypharmacy in patients with cardiovascular disease by providing guidance on deprescribing strategies applicable across different age groups. They highlight the prevalence and adverse outcomes associated with polypharmacy, emphasizing the need for tailored approaches that involve clinical cues, validated tools, and collaborative decision-making among healthcare teams. This scientific statement seeks to fill the existing gaps in the literature regarding effective deprescribing practices for both cardiovascular and non-cardiovascular medications.
This is one of 33,000+ journals available on OSLR. Try it free for 14 days.
Free 14-day trial. 33,000+ journals. Cancel anytime.
More from Circulation
View all →Jul 9, 2026 · Circulation
Exercise Training in High-Risk Populations: A Scientific Statement From the American Heart Association
Jul 6, 2026 · Circulation
Cardiovascular Risk Reduction With GLP-1 RA Drugs
Jun 29, 2026 · Circulation
AHA/ACC/ESC/WHF Expert Consensus Document: Second Universal Definition of Heart Failure (2026)
Jun 26, 2026 · Circulation
Advancing Quality in the Evaluation, Surveillance, and Management of Aortic Stenosis: A Report From the AHA Target: AS Registry
Jun 24, 2026 · Circulation
Heart Failure Occurring in the Perinatal Period: A Scientific Statement From the American Heart Association
Jun 22, 2026 · Circulation
Challenges and Future Trends in Large Vessel Vasculitis
More in Thoracic Surgery (Cardiothoracic Vascular Surgery)
View all →Jul 10, 2026 · Lancet (London, England)
Advancing the relevance of clinical trials for older patients
Jul 9, 2026 · Lancet (London, England)
Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial
Jul 9, 2026 · JAMA
Formulary-Related Insurance Denials of Single-Source Branded Drugs in the United States
Jul 9, 2026 · Lancet (London, England)
Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations
Jul 9, 2026 · Lancet (London, England)
Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial
Jul 8, 2026 · The New England journal of medicine
Meningococcal B Vaccine to Prevent <em>Neisseria gonorrhoeae</em> Infection
"Oslr has become part of my weekly routine on my day off. The clinical relevance of the summaries is outstanding — I'd rate it 9/10. Being able to consume research hands-free is a huge advantage for busy physicians."
Dr. Jennifer Thompson
Portland, OR
Stay current without falling behind
33,000+ journals. 3-minute audio summaries. Free for 14 days.
